These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3423040)

  • 21. Platelet activation by platelet aggregation factor from Eisenia foelide.
    Qian R; Zhou YC; Zhuang QQ
    Zhongguo Yao Li Xue Bao; 1994 Sep; 15(5):432-5. PubMed ID: 7717070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevation of serum thrombopoietin precedes thrombocytosis in Kawasaki disease.
    Ishiguro A; Ishikita T; Shimbo T; Matsubara K; Baba K; Hayashi Y; Naritaka S; Nakahata T
    Thromb Haemost; 1998 Jun; 79(6):1096-100. PubMed ID: 9657430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current viewpoints in the pathogenesis of Kawasaki disease].
    Bollen CW; Rijkers GT; Zegers BJ; de Graeff-Meeder ER
    Ned Tijdschr Geneeskd; 1995 Mar; 139(11):549-54. PubMed ID: 7700390
    [No Abstract]   [Full Text] [Related]  

  • 24. Cytopathogenic protein (CPP) produced by Propionibacterium acnes isolated from patients with Kawasaki disease.
    Tomita S; Koga Y; Inoue O; Fujimoto T; Kato H
    Prog Clin Biol Res; 1987; 250():73-80. PubMed ID: 3423083
    [No Abstract]   [Full Text] [Related]  

  • 25. Renal histology of mucocutaneous lymph node syndrome (Kawasaki disease).
    Salcedo JR; Greenberg L; Kapur S
    Clin Nephrol; 1988 Jan; 29(1):47-51. PubMed ID: 3289806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Synthesis and platelet aggregating activity of structural analogs of platelet-activating factor with a heterocyclic head group].
    Kertscher HP; Ostermann G
    Pharmazie; 1987 Nov; 42(11):713-5. PubMed ID: 3438334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Inhibition of platelet aggregation by immune complexes. I. Clinical studies].
    Shkhvatsabaia IK; Osipov SG; Turlubekov KK; Titov VN; Kasatkina LV
    Biull Eksp Biol Med; 1982 Nov; 94(11):27-9. PubMed ID: 7150731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antibody-dependent cell-mediated cytotoxicity (K-cell population) of peripheral lymphocytes in Kawasaki disease and allergic conditions. 1. Relation between K-cell population and the blood immune complex content in Kawasaki disease].
    Suzuki M
    Arerugi; 1983 Mar; 32(3):164-72. PubMed ID: 6625894
    [No Abstract]   [Full Text] [Related]  

  • 29. Immune complex study of biopsy specimens from Kawasaki disease patients.
    Fujimoto T; Kato H; Inoue O; Tomita S; Koga Y
    Prog Clin Biol Res; 1987; 250():209-17. PubMed ID: 3321077
    [No Abstract]   [Full Text] [Related]  

  • 30. Kawasaki disease. Some recent studies on pathogenetic mechanisms.
    Tay JS
    J Singapore Paediatr Soc; 1990; 32(1-2):11-3. PubMed ID: 1701839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The binding of bovine platelet aggregating factor to human platelets.
    Brown JE; Thuy LP
    Thromb Res; 1981 Apr 1-15; 22(1-2):41-51. PubMed ID: 7292446
    [No Abstract]   [Full Text] [Related]  

  • 32. Recurrent mucocutaneous lymph node syndrome (Kawasaki disease): a report of three cases.
    Keren G; Passwell J; Cohen BE
    J Med; 1986; 17(5-6):365-71. PubMed ID: 3473170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mucocutaneous lymph node syndrome of Kawasaki disease. Presentation of a case].
    Zulaica D; Alonso M; Ortega J; Pérez Yarza E; Damiano A
    Rev Clin Esp; 1981 Nov; 163(4):265-7. PubMed ID: 7335936
    [No Abstract]   [Full Text] [Related]  

  • 34. Reactions of immunoglobulin G-binding ligands with platelets and platelet-associated immunoglobulin G.
    Rosse WF; Devine DV; Ware R
    J Clin Invest; 1984 Feb; 73(2):489-96. PubMed ID: 6699173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evidence for a possible role of the mite antigen in Kawasaki disease].
    Furusho K; Sato K; Soeda T; Okabe T; Hirota T
    Nihon Rinsho; 1983 Sep; 41(9):2017-22. PubMed ID: 6229653
    [No Abstract]   [Full Text] [Related]  

  • 36. A new platelet aggregating material (PAM) in an experimentally induced rat fibrosarcoma.
    Mohanty D; Hilgard P
    Thromb Haemost; 1984 Apr; 51(2):192-5. PubMed ID: 6740552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kawasaki disease: monitoring of circulating immune complexes.
    Salo E; Kekomäki R; Pelkonen P; Ruuskanen O; Viander M; Wagner O
    Eur J Pediatr; 1988 May; 147(4):377-80. PubMed ID: 3294012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet aggregating material (PAM) of two virally-transformed tumors: SV3T3 mouse fibroblast and PW20 rat renal sarcoma. Role of cell surface sialylation.
    Karpatkin S; Pearlstein E; Salk PL; Yogeeswaran G
    Prog Clin Biol Res; 1982; 89():445-77. PubMed ID: 7111309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Complement-binding activity of myeloma and normal immune complexes].
    Lavrent'ev VV; Konstantinova NA; Tumanova IA
    Biull Eksp Biol Med; 1986 Feb; 101(2):183-5. PubMed ID: 3947736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphocyte abnormalities and complement activation in Kawasaki disease.
    Laxer RM; Schaffer FM; Myones BL; Yount WJ; Rowe RD; Rubin L; Stein LD; Gelfand EW; Silverman ED
    Prog Clin Biol Res; 1987; 250():175-84. PubMed ID: 3423037
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.